Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 12/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.43 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716954 | 1.00 | OPRK1 (0.44) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL714751 | 0.89 | DYRK3 (0.46) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL714750 | 0.89 | DYRK3 (0.46) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL716284 | 0.85 | OPRK1 (0.41) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL716285 | 0.85 | OPRK1 (0.41) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL713435 | 0.84 | AKT1 (0.42) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL713436 | 0.84 | AKT1 (0.42) | OPRK1DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2113711 | 0.79 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL2113713 | 0.79 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL2117490 | 0.77 | OPRK1 (0.38) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | OPRK1 416/4885DYRK3 419/4885PIM3 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.